What can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension?
Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. tamukou@med.yokohama-cu.ac.jp
Kouichi
K
Tamura
Masato
M
Ohsawa
Tomohiko
T
Kanaoka
Akinobu
A
Maeda
Kengo
K
Azushima
Kazushi
K
Uneda
Hiromichi
H
Wakui
Koichi
K
Azuma
Yuko
Y
Tsurumi-Ikeya
Satoshi
S
Umemura
D047228:Angiotensin II Type 1 Receptor Blockers / Q000378:metabolism*; D000818:Animals; D001562:Benzimidazoles / Q000378:metabolism*; D001713:Biphenyl Compounds; D006801:Humans; D010069:Oxadiazoles / Q000378:metabolism*; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D013777:Tetrazoles / Q000378:metabolism*
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D010069:Oxadiazoles; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; C521273:azilsartan; C081643:candesartan